Remove 2003 Remove Marketing Remove Pharmaceuticals Remove Pharmacy
article thumbnail

Marquis Who’s Who Honors James D. McChesney, PhD, with Inclusion in Who’s Who in the World

The Pharma Data

McChesney served as a faculty member at the University of Kansas School of Pharmacy, who presented him with an Outstanding Teaching Award for the 1967 to 1968 academic year. departing in 2003 to become the chief scientific officer for Tapestry Pharmaceuticals and ChromaDex Inc.

article thumbnail

The FDA and Feasible Alternative Designs

Drug & Device Law

In product liability litigation generally, plaintiffs have been allowed to invent all kinds of “alternative” designs as long as some “expert” opines that the design (even if never before marketed) is “feasible.” 2003), aff’d , 810 N.Y.S.2d For physicians to prescribe such a safer drug, it must reach the market. 2d 506 (N.Y.

FDA 59
article thumbnail

NPP, DCC, And FDA-Regulated Medical Products

Drug & Device Law

The word “generic” in that sentence was not limiting, as the logic applied more broadly: “Nor could such a state law duty exist, as it would directly conflict with the federal statutory scheme in which Congress vested sole authority with the FDA to determine whether a drug may be marketed in interstate commerce.” Id. Walsh , 538 U.S.